Abstract
Objective Recent studies reported the intraluminal thrombus (ILT) among others strongly affects abdominal aortic aneurysms (AAA) expansion rates. Thus, we investigate characteristics of ILT with AAA expansion.
Methods We applied homogeneous multistate continuous-time Markov chain models to longitudinal data of 26 Korean AAA patients as a retrospective clinical study. We considered four states of AAA and maximal thickness of ILT (maxILT), fraction of wall area covered by ILT (areafrac) and fraction of ILT volume (volfrac) as possible covariates.
Results Based on likelihood-ratio statistics, areafrac is the most significant biomarker and maxILT is the second most significant. Besides, within AAAs that developed an ILT layer, we found that an AAA expands relatively fast at an early stage but the rate goes slower once AAA reaches in a large size.
Conclusion Results recommends surgical intervention when any patient with areafrac more than 60% or maxILT more than 30mm. Although this recommendation should be considered with caution given the limited sample size, one can use the proposed model as a tool to find such recommendations with their own data.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors gratefully acknowledge the support, in part, by the National Heart, Lung, and Blood Institute of the National Institutes of Health (R01HL115185 and R21HL113857) and National Science Foundation (CMMI-1150376). Choi and Lim were supported in part by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (2018R1A4A1025986 and 2019R1A2C1002213).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Michigan State University(MSU) IRB reviewed and determined that the study does not involved human subjects as defined in 45 CFR 46. 162 (f).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available on request from the corresponding author.
